FOOD ALLERGIES AND PEANUT ALLERGIES

Food allergies cause over 30,000 incidents of anaphylaxis and 100 – 200 deaths in the US each year. Peanut allergy is highly problematic, with more than 1.5 million Americans impacted; life-threatening anaphylaxis can be induced by trace exposure. A diagnosis of peanut allergy means maintaining constant dietary vigilance to reduce the risk of accidental peanut-induced anaphylaxis. In the case of children, this vigilance must also be maintained by parents, schools, and other guardians.

There is no FDA-approved treatment for preventing dangerous peanut-induced allergic reactions. Immunotherapy, or administering increasing doses of an allergen to induce tolerance, leads to adverse reactions in the majority of patients undergoing peanut immunotherapy. There is a dire need for effective treatments that can provide lasting protection.

PEANUT ALLERGIES & ASP0892™

ASP0892 (formerly known as ARA-LAMP-Vax) is an investigational vaccine for treating patients suffering with food allergies to peanut, one of the most potent and problematic food allergies in the world. Astellas Pharmaceuticals, Inc is leading the full development of ASP0892, as part of the exclusive licensing agreement for LAMP-Vax platform signed/executed on October 2015.

ASP0892™ – ADDRESSING AN UNMET NEED

ASP0892™ (formerly ARA-LAMP-Vax) is a novel hypoallergenic treatment that aims to significantly reduce or eliminate sensitivity to the three major peanut allergens. By directing the synthesized peanut allergen-LAMP fusion protein directly into the MHC-II lysosome compartment, ASP0892 is designed to generate a Th1–mediated immune response without exposing the patient systemically to free, native peanut allergen.